Repligen Corporation | Stephens

Who We Are

What We Do

We provide investment banking, research, sales and trading, asset and wealth management, public finance, insurance, private capital, and family office services.

About Us

We are a family-owned financial services firm that values client relationships, long-term stability, and supporting the communities where we live and work.

The Stephens Story

The idea of family defines our culture, because each of us knows that our reputation is on the line as if our own name was on the door.

Leadership

Our reputation as a leading independent financial services firm is built on the stability of our longstanding and highly experienced senior executives.

Impact Initiatives

We are committed to corporate philanthropy; economic and financial literacy advocacy; and diversity, equity, and inclusion initiatives.

Our Brand Ambassadors

Stephens is proud to sponsor the PGA TOUR, LPGA Tour, and PGA TOUR Champions careers, as well as applaud the philanthropic endeavors, of our Brand Ambassadors.

Stephens & Williams Racing Partnership

Stephens is the official investment banking partner of Williams Racing, one of the most winning teams in F1 history. We share that tradition of success.

Making Connections

We host many highly informative meetings each year with clients, industry decision makers, and thought leaders across the U.S. and in Europe.

Back to transactions
Co-Manager

Repligen Corporation

$272 Million 12/07/2020 Life Sciences & Medical Devices Complete
Public Companies
Show Tombstone

Transaction Details

  • On December 7, 2020, Repligen Corporation (“Repligen” or the “Company”) announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock at a price to the public of $181.00 per share
    • The offering consisted of 100% primary shares
  • Repligen also granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of its common stock
  • Repligen intends to use the net proceeds from the offering for working capital and other general corporate purposes, including potential future acquisitions or investments in complementary businesses, products, services, and technologies

About the company

Repligen Corporation
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. The Company’s primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Repligen’s corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of Repligen’s manufacturing sites are located in the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S., the Company hassitesin Estonia, Germany, Ireland, the Netherlands and Sweden.

Sources: Company filings and pressrelease
  1. This material has been prepared solely for informative purposes as of its stated date and is not a solicitation, or an offer, to buy or sell any security. It does not purport to be a complete description of the securities, markets, or developments referred to in the material. Information included in the material was obtained from sources w which we consider reliable, but we have not independently verified such information and do not guarantee that it is accurate or complete. No subsequent publication or distribution of this material shall mean or imply that any such information or opinion remains current at any time after the stated date of the material. We do not undertake to advise you of any changes in any such information or opinion. Additional information is available upon request.

  2. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from Stephens Inc.’s Equity Syndicate Desk, at Stephens Inc., 111 Center Street, Little Rock, AR 72201, ATTN: Equity Syndicate Desk, or from the Securities and Ex change Commission’s website at www.sec.gov at the following link:. https://www.sec.gov/Archives/edgar/data/730272/000119312520311156/d90736d424b5.htm. A registration statement relating to these securities has been filed with the Securities and Exchange Commission. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to the notice of its acceptance given after the effective date.

  3. “Stephens” is the brand name for a family of independent privately held financial services firms, including Stephens Europe Limited, which is authorized and regulated by the Financial Conduct Authority (Registered office 36-38 Cornhill, London, EC3V 3NG, Registered number 8817024) and Stephens Inc. which is regulated by the United States Securities and Exchange Commission and the Financial Industry Regulatory Authority (Home Office: 111 Center Street, Little Rock, AR USA, 501-377-2000). Stephens Inc. is a member of NYSE and SIPC. For more information, visit www.stephens.com. © 2020 Stephens